Document is current

Article History

Received: 13 February 2023

Accepted: 15 July 2024

First Online: 13 August 2024

Declarations

:

: No informed consent was required, as anonymised patient data was used in the analyses, in according to the laws for the protection of privacy (AVG). The study was conducted in accordance with the guidelines of the declaration of Helsinki and the principles of Good Clinical Practice. The study was approved by the Institutional Review Board of the Erasmus MC (MEC-2020–0751).

: Not applicable.

: Frank Tacke received research grants from Gilead, Allergan, Bristol-Myers Squibb, and Inventiva. Thomas VanWolleghem has received grants from Gilead Sciences, Roche, and Bristol Myers Squibb; served as a consultant for Janssen Pharmaceuticals, Gilead Sciences, AbbVie, Bristol Myers Squibb; and served as a sponsored lecturer for W.L. Gore, Gilead Sciences, and Bristol Myers Squibb. Stefan Zeuzem has received speaking and/or consulting fees from Abbvie, BioMarin, Gilead, GSK, Intercept, Janssen, Merck/MSD, NovoNordisk, SoBi, and Theratechnologies. Heiner Wedemeyer has received research grants from AbbVie, Biotest, Gilead Sciences, Merck Sharp and Dohme, and Roche; consultancy fees from AbbVie, Aligos, Altimmune, Biotest, Bristol-Myers Squibb, BTG, Dicerna, Enanta, Gilead Sciences, Janssen, Merck Sharp and Dohme, MYR GmbH, Roche and Vir Biotechnology; honoraria from AbbVie, Biotest, Gilead Sciences and Merck Sharp and Dohme; funds from AbbVie, Altimmune, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp and Dohme, MYR GmbH, Novartis and Vir Biotechnology as principal investigator for clinical trials. Christian Trautwein Received grants/research support from Abbvie, BMS, Gilead, Intercept, Merz, Norgine, Novartis. Received honoraria/consultation fees or served on the advisory board for Bayer, Gilead, GSK, Falk Foundation, Intercept and Roche.Frank Tacke received research grants from Gilead, Allergan, Bristol-Myers Squibb, and Inventiva. Thomas VanWolleghem has received grants from Gilead Sciences, Roche, and Bristol Myers Squibb; served as a consultant for Janssen Pharmaceuticals, Gilead Sciences, AbbVie, Bristol Myers Squibb; and served as a sponsored lecturer for W.L. Gore, Gilead Sciences, and Bristol Myers Squibb. Stefan Zeuzem has received speaking and/or consulting fees from Abbvie, BioMarin, Gilead, GSK, Intercept, Janssen, Merck/MSD, NovoNordisk, SoBi, and Theratechnologies. Heiner Wedemeyer has received research grants from AbbVie, Biotest, Gilead Sciences, Merck Sharp and Dohme, and Roche; consultancy fees from AbbVie, Aligos, Altimmune, Biotest, Bristol-Myers Squibb, BTG, Dicerna, Enanta, Gilead Sciences, Janssen, Merck Sharp and Dohme, MYR GmbH, Roche and Vir Biotechnology; honoraria from AbbVie, Biotest, Gilead Sciences and Merck Sharp and Dohme; funds from AbbVie, Altimmune, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp and Dohme, MYR GmbH, Novartis and Vir Biotechnology as principal investigator for clinical trials. Christian Trautwein Received grants/research support from Abbvie, BMS, Gilead, Intercept, Merz, Norgine, Novartis. Received honoraria/consultation fees or served on the advisory board for Bayer, Gilead, GSK, Falk Foundation, Intercept and Roche. Thomas Berg received grants/research support from Abbvie, BMS, Gilead, MSD/Merck, Humedics, Intercept, Merz, Norgine, Novartis, Orphalan, and Sequana Medical; received honoraria/consultation fees or served on the advisory board for Abbvie, Alexion, Bayer, Gilead, GSK, Eisai, Enyo Pharma, Falk Foundation, HepaRegeniX GmbH, Humedics, Intercept, Ipsen, Janssen, MSD/Merck, Novartis, Orphalan, Roche, Sequana Medical, SIRTEX, SOBI, and Shionogi; participated in a company-sponsored speaker’s bureau for Abbvie, Alexion, Bayer, Gilead, Eisai, Intercept, Ipsen, Janssen, MedUpdate GmbH, MSD/Merck, Novartis, Orphalan, Sequana Medica, SIRTEX, and SOBI. Rob de Knegt has received honoraria for consulting/speaking from Gilead, Janssen, Echosens, AbbVie, and Norgine and received research grants form Gilead and Janssen. The other authors have no conflict of interest in relation to the contents of this manuscript.Thomas Berg received grants/research support from Abbvie, BMS, Gilead, MSD/Merck, Humedics, Intercept, Merz, Norgine, Novartis, Orphalan, and Sequana Medical; received honoraria/consultation fees or served on the advisory board for Abbvie, Alexion, Bayer, Gilead, GSK, Eisai, Enyo Pharma, Falk Foundation, HepaRegeniX GmbH, Humedics, Intercept, Ipsen, Janssen, MSD/Merck, Novartis, Orphalan, Roche, Sequana Medical, SIRTEX, SOBI, and Shionogi; participated in a company-sponsored speaker’s bureau for Abbvie, Alexion, Bayer, Gilead, Eisai, Intercept, Ipsen, Janssen, MedUpdate GmbH, MSD/Merck, Novartis, Orphalan, Sequana Medica, SIRTEX, and SOBI. Rob de Knegt has received honoraria for consulting/speaking from Gilead, Janssen, Echosens, AbbVie, and Norgine and received research grants form Gilead and Janssen. Solko Schalm is the unpaid director of TherapySelector B.V., a socially oriented company that has developed the TherapySelector instrument. Neither he nor the company was involved in the design, funding, conduct or data analysis of the study. He provided the TherapySelector instrument information, was helpful in providing access to the annual editions of the database and gave suggestions about the manuscript text. Neither he nor the Therapy Selector company have received any financial contribution from pharmaceutical companies. The other authors have no conflict of interest in relation to the contents of this manuscript.